Rising healthcare costs are a huge problem in the U.S., though the biggest spenders in the healthcare system are concentrated to a small population.

The drug industry is not happy about a new plan from the Trump administration that would allow cheaper drugs to be imported from Canada. The initiative, called the Safe Importation Action Plan, was announced by HHS July 31.

Average Medicare Part D premiums have dropped for the third year in a row, according to CMS, and they are projected to decline again in 2020. Medicare Part D plans offer prescription drug coverage to Medicare beneficiaries.

HHS is launching a new action plan for the safe importation of certain prescription drugs to bring in medications from foreign markets. The Safe Importation Action Plan extends recent initiatives from the Trump administration to make prescription drugs cheaper in the U.S.

Just a day after announcing three new payment proposals for 2020, CMS introduced a new pilot program for clinicians focusing on data.

CMS unleashed a slew of proposals July 29, including 2020 payment rule proposals and a requirement for hospitals to publish the payer-specific negotiated prices of healthcare services.

Pfizer, one of the nation’s largest pharmaceutical companies, is merging its off-patent and generic drug business with Mylan, a global generic and specialty pharmaceutical company based in the Netherlands. The spinoff deal is expected to close mid-2020, pending shareholder and regulatory approvals.

President Trump is reportedly working on another executive order targeting rising drug prices, according to Reuters.